From: Vitamin D and breast cancer: interpreting current evidence
 |  |  | Adjuvant therapy |  |  | |
---|---|---|---|---|---|---|
Lead author | n | Category | Hormonal therapy | Chemotherapy | Mean follow-up (years) | Study outcome |
Goodwin | 512 | Early breast cancer, resected | Tamoxifen per clinical decision | Varies per clinical decision | 11.6 | Deficient (<50 nmol/l) vs. sufficient (>72 nmol/l) 25(OH)D levels, in multivariant adjusted analysesa |
 |  | Cohort |  |  |  | Distant recurrence HR = 1.71 95% CI = 1.02 to 2.86a |
 |  | Premenopausal and postmenopausal |  |  |  | Survival HR = 1.60, 95% CI = 0.96 to 2.64 |
Piura | 622 | Early breast cancer, resected | Tamoxifen for 53 years vs. tamoxifen for 53 years + octreotide for 2 years (per protocol) | Varies per clinical decision | 7.9 | No significant association with event-free survival or relapse-free survival with 25(OH)D level |
 |  | Cohort within a randomized clinical trial Postmenopausal |  |  |  |  |
Jacobs | 1,024 | Early breast cancer, resected entered within 43 years from diagnosis Nested case-control within a randomized clinical trial | Varies per clinical decision | Varies per clinical decision | 7.3 | No significant association with breast cancer recurrence (local, regional, or distant) or death with 25(OH)D level |
 |  | Premenopausal and postmenopausal |  |  |  |  |